Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Sandoz contributes to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. That is our purpose.
Our broad portfolio is backed by a range of state-of-the-art technologies, formulations, and devices.
Our global portfolio comprises approximately 1000 molecules, covering all major therapeutic areas. Our broad offering translates into substantial and ongoing savings for patients and payers, which helps to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.